Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

terminated117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

NCT05281510
terminatedphase_1

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

NCT05458102
completedphase_1

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

NCT03060447
completedphase_2

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

NCT02166047
completedphase_2

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

NCT02579382
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05281510Phase 2

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

Completed
NCT05458102Phase 1

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

Terminated
NCT03060447Phase 1

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

Completed
NCT02166047Phase 2

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

Completed
NCT02579382Phase 2

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Completed
NCT02858401Phase 1

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6